No Data
No Data
We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate
MediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company's Future
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Strategic Growth and Market Potential Drive Buy Rating for MediWound Despite Revenue Decline